Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 6, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director disclosures rather than financial performance metrics.
Material Changes
The filing details specific changes in shareholdings for directors and employee trusts during early October 2003:
- Employee Trust Transfer: On October 2, 2003, the GSK Trust transferred 4,000 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Dr. J-P Garnier (ADR Increase): Dr. Garnier increased his interest by 1,040.867 Ordinary Share ADRs at $43.025 per ADR following dividend reinvestment on October 2, 2003.
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,855,176 to 18,828,820 due to fund movements on October 2, 2003, at an average price of $43.01.
- Mr. J D Coombe (Share Acquisition): Mr. Coombe acquired 3 Ordinary Shares at £12.65 per share through the Dividend Reinvestment element of the ShareReward Plan on October 2, 2003.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director shareholding changes.
Key Facts for Investor Verification
- Verify the total number of shares held by directors Dr. J-P Garnier and Mr. J D Coombe following these specific transactions.
- Confirm the impact of the 4,000 share transfer from the GSK Trust on the company's outstanding share count.
- Note the share price references used in these transactions: $43.025 and $43.01 for ADRs, and £12.65 for Ordinary Shares.